Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

AI-generated analysis

🤝 Regeneron has entered an agreement with the U.S. government to lower drug costs for American patients while providing a new gene therapy for free.

🎧 The company will offer Otarmeni™ (lunsotogene parvec-cwha), its newly approved gene therapy for ultra-rare genetic hearing loss, at no cost in the U.S.

💰 Medicaid prices for Regeneron's medicines will be reduced to align with those charged in other developed countries.

📉 Future U.S. medicine prices will be aligned with pricing set by a defined group of other high-income nations.

💊 Praluent ® (alirocumab) will become available for direct patient purchase via the TrumpRx.gov platform at most-favored nation pricing.

🏛️ CEO Dr. Leonard Schleifer stated that American patients should not subsidize lower drug prices in other high-income nations that do not contribute their fair share.

🔬 Regeneron's leadership joined President Donald J. Trump and his Administration at the White House to discuss the terms of this new agreement.

🏭 The company is exempt from future pricing mandates and will receive three years of tariff relief under a Commerce Department agreement.

💵 Regeneron has already committed over $9 billion in U.S.-based manufacturing and R&D infrastructure investments for coming years.

🚫 Specific additional terms of the agreement have been kept confidential between Regeneron and the government.

📰 Regeneron plans to continue its large-scale investment in domestic research and development despite the new commitments.

🧬 Otarmeni treats severe to profound hearing loss caused by variants of the otoferlin gene, marking Regeneron's first gene therapy for this condition.

🔒 The press release includes standard forward-looking statements regarding risks and uncertainties about future events and performance.

🌐 Regeneron remains a leading biotechnology company focused on life-transforming medicines for serious diseases across multiple therapeutic areas.

Bullish Signals
  • Regeneron has agreed to provide its innovative gene therapy, Otarmeni™ (lunsotogene parvec-cwha), for free in the U.S. to treat patients with severe to profound genetic hearing loss.
  • The company will lower Medicaid prices based on prices set in other developed countries, aligning future U.S. medicine prices with this defined group of countries.
  • Praluent ® (alirocumab) will be available for direct patient purchase through TrumpRx.gov at the most-favored nation price.
  • Regeneron is not subject to future pricing mandates and has secured three years of tariff relief through an agreement with the U.S. Department of Commerce.
  • The company has already committed over $9 billion in U.S.-based manufacturing and R&D infrastructure investments in coming years, reinforcing its domestic capacity.
  • Regeneron will continue to invest deeply in its biotech ecosystem and domestic innovation without being constrained by unfavorable pricing policies.
Risk Factors
  • Regeneron's commitment to provide Otarmeni™ gene therapy for free in the U.S. creates a significant opportunity cost as the company forgoes revenue from an approved, innovative treatment that could have generated substantial sales.
  • The agreement requires Regeneron to lower Medicaid prices by aligning them with prices in other developed countries, potentially reducing profit margins on existing and future medicines in the high-cost U.S. market.
  • Future pricing mandates for Regeneron are excluded from this agreement, but the reliance on confidential terms suggests potential uncertainty regarding long-term commercial terms or regulatory obligations.
  • The company's assertion that 'viliying the biopharma industry has not produced lower prices' highlights ongoing political and public scrutiny that could lead to further price pressures beyond current commitments.
Full Analysis
On April 23, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a significant agreement with the U.S. government aimed at reducing drug costs for American patients while ensuring continued access to innovative treatments. The deal addresses four requests outlined in President Donald J. Trump’s letter dated July 31st of the same year. As part of this pact, Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), a recently approved gene therapy for an ultra-rare form of genetic hearing loss caused by variants of the otoferlin gene, completely free of charge in the United States. This therapy targets patients with severe to profound hearing loss who lack access to existing treatments. The agreement includes substantial pricing adjustments for other Regeneron products to align costs more equitably across developed nations. Specifically, Regeneron has committed to lowering Medicaid prices by basing them on prices set in other high-income countries and will apply this same alignment principle to future medicines developed in the U.S. Additionally, Praluent ® (alirocumab), a cardiovascular medicine, will be made available for direct patient purchase through the TrumpRx.gov platform at the most-favored nation price. Regeneron executives emphasized that for too long American patients and taxpayers have subsidized lower prices in other high-income nations, and this move seeks to equilibrate global prices while preserving domestic innovation. In return for these commitments, including the provision of Otarmeni™ for free and the implementation of the pricing framework, Regeneron will not be subject to future pricing mandates. The company has also secured three years of tariff relief through an agreement with the U.S. Department of Commerce, contingent on specific activities and investments to support R&D and manufacturing in the United States. Regeneron reinforces its commitment to domestic growth, stating it remains one of the largest manufacturers of biologics globally and has already pledged over $9 billion in U.S.-based manufacturing and research infrastructure investments. Co-founders Leonard Schleifer, M.D., Ph.D., and George Yancopoulos, M.D., Ph.D., joined President Trump at the White House to highlight that the biopharmaceutical industry can be a genuine force for good through such public-private collaboration.